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Summary The MAC 16 is a transplantable murine carcinoma of the colon producing extensive weight loss in
tumour-bearing animals. The weight loss is proportional to the size of the tumour and occurs without a
reduction in food intake when compared with non tumour-bearing control mice. Weight loss produced by the
MAC 16 tumour is accompanied by hypoglycaemia which becomes more extensive as the tumour mass
increases.
In order to understand the mechanism of the cachexia produced by the MAC 16 tumour the rate of
substrate utilization and CO2 formation from both glucose and palmitate has been compared in vitro, with
other colon carcinoma cell lines known not to produce cachexia as well as a range of murine and human
tumour cell lines. The rate of glucose consumption, lactate production and CO2 formation from both glucose
and palmitate is much higher for the MAC 16 than for the other tumour cells. For all cell lines in vitro the
consumption of glucose exceeds that of palmitate by a factor of 103. Excessive consumption of glucose by the
MAC 16 tumour may account for the hypoglycaemic effect on the host. The level of 3 oxo acid CoA
transferase, an ihitiator of ketone body utilization, was found to be much lower in the MAC 16 tumour than
non-involved colon. This suggests that the tumour may not be able to metabolize ketone bodies effectively.
The MAC 16 is a chemically induced transplantable
adenocarcinoma of the colon which produces
extensive weight loss in tumour-bearing mice
without a reduction in overall food intake (Bibby et
al., 1986). Weight loss appears to be directly related
to the size of the tumour and is apparent at small
tumour masses (less than 1% of the host body
weight). We have considered this tumour to be an
appropriate model of human cachexia where weight
loss originates from a metabolic effect of the
tumour.
During the phase of host weight loss in mice
bearing the MAC 16 tumour extensive mobilization
of adipose tissue occurs with a corresponding rise
in the plasma level of free fatty acids (FFA),
although there is not a marked ketosis as might be
expected in simple starvation (Tisdale et al., 1985).
The tumour also has a marked hypoglycaemic
effect on the host. We have reduced the host weight
loss produced by the MAC 16 tumour by feeding a
diet with increasing proportions of energy derived
from medium chain triglycerides. In addition this
dietary regime produced marked reductions in
tumour size, suggesting the inability of the tumour
to utilize fat as an energy source (Tisdale et al.,
1986).
This study compares the rate of substrate
utilization and oxidative metabolism of MAC 16
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tumour cells in vitro with other colon carcinoma
cell lines known not to produce cachexia in the host
as well as a range of murine and human tumour
cells. In addition the levels of enzymes involved in
the metabolism of ketone bodies in the MAC 16
tumour have been compared with those in the non-
involved host tissues to assess the ability of the
MAC 16 to utilize ketone bodies under a ketogenic
regime.
Materials and methods
D-[U-14C]Glucose (sp. act. 270 mCi mmol-1) and
[U-14C] palmitic acid (sp. act. 403 mCi mmol-1)
were purchased from Amersham International,
Bucks. Culture media and foetal calf serum were
purchased from Gibco Europe, Scotland. All other
chemicals were obtained from Sigma Chemical Co.,
Dorset.
Tumour system
The MAC tumours are a series of transplantable
adenocarcinomas of the large bowel of mice from
primary tumours induced by prolonged adminis-
tration of 1,2-dimethyl hydrazine (Double & Ball,
1975). Tumours were passaged in pure strain
NMR1 mice (age 6-8 weeks). The tumour was
excised from donor animals and placed in sterile
0.9% saline containing streptomycin and penicillin
and cut into small fragments 1 x 2mm in size. The
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fragments were implanted into the flank using a
trocar. Both tumour tissue and blood from tumour-
bearing animals was subjected to bacteriological
screening. Mice were fed rat and mouse breeding
diet purchased from Pilsbury's Ltd., Birmingham,
UK. Of the MAC tumours only the MAC 16
shows extensive weight loss in tumour-bearing
animals. Both the MAC 13 and MAC 15A are
colon adenocarcinomas with a similar histology to
the MAC 16. Mice bearing the TLX5 lymphoma or
L1210 leukaemia also show no evidence of weight
loss. There was also no report of weight loss in
patients from which the original isolates of human
tumours were obtained.
Cell lines and culture conditions
L132 (normal human lung epithelial cell line) was
grown in Dulbecco's Modified Eagle's Medium.
MAC 16, MAC 13, MAC 15A, Raji (Burkitts
lymphoma), GM 892A, GM 0621 (transformed
human lymphoblastoid) K562 (human myeloid
leukaemia), HL60 (human acute promyelocytic
leukaemia), TLX5 (murine lymphoma) and L1210
(murine lymphatic leukaemia) were maintained in
RMPI 1640 media. All media were supplemented
with 10% foetal calf serum and were maintained in
an atmosphere of 5% CO2 in air except Dulbecco's
medium where 10% CO2 was used.
Substrate utilization
For the determination of 14CO2 production either
D-[U-14C] glucose (0.2!LCiml-1) or [U-14C]
palmitic acid (0.67pCiml 1 plus 3.57j mol sodium
palmitate ml -1) were added to cells (1-
3 x 106ml-1) in 10ml portions in culture flasks
equipped with suba seals and a centre well. At
various time periods up to 24h 0.3ml of 3N NaOH
was injected into the centre well and 0.5ml of 2N
perchloric acid was injected through the rubber cap
to stop the reaction and release 14CO2 from the
medium. After a further 1 h of incubation, in order
to ensure complete absorption of the released
14CO2 into the alkaline solution, the contents of
the centre wdowere combined with 10ml Optiphase
scintillation fluid (Fisons, Loughborough) and the
radioactivity determined.
The glucose consumption and lactate production
were determined on separate non-radioactive
incubations. Glucose was measured by the o-
toluidine reagent kit (Sigma Chemical Co., Dorset)
and lactate levels were measured using the method
of Gutman & Wahlefield (1974). The glucose
concentration of RPMI 1640 medium was 2g 1
and Dulbecco's modified Eagle's media was 4gI1
The respective lactate concentrations were 4 and
8mM. All media contained 15 ugml1 of free fatty
acids.
Enzymes ofketone body metabolism in MAC 16
tumour and normal mouse tissues
Animals were killed by cervical dislocation 24 days
after tumour transpltantation. Tissues for enzyme
determination were quickly removed onto ice,
weighed and prepared for enzyme analysis as
previously described (Tisdale & Brennan, 1983).
Protein was determined by the method of Lowry et
al. (1951), using bovine serum albumin as a
standard. The following enzymes were assayed as
previously described (Tisdale & Brennan, 1983): 3-
hydroxybutyrate dehydrogenase (EC 1.1.1.30), 3
oxo acid - CoA transferase (EC 2.8.3.5) and
acetoacetyl CoA thiolase (EC 2.3.1.9).
Results
The MAC 16 tumour produces extensive host body
weight loss. In males almost 20% of the total body
weight is lost within 30 days after tumour
transplantation (Figure 1) and in females as much
as 33% when compared with age matched controls.
Weight loss occurs even with a small tumour
burden and increases with increasing weight of
tumour (Figure 2). The first significant loss of
weight occurs around 14 days after tumour trans-
plantation when the tumour mass is only -0.2g
(<1% of the host weight). The host weight
reduction occurs without a measurable drop in
food intake. Concomitant with the reduction in
host weight there is also a decrease in the level of
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Figure 1 Mean body weight of male NMR1 mice
either implanted with MAC 16 tumour on day 0 (0)
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Figure 2 Relationship between carcass weight and
tumour weight in male NMRI mice bearing the
MAC 16 tumour.
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Figure 3 Blood glucose concentration in tumour-
bearing (A) and non tumour-bearing (0) NMR1 mice
after tumour transplantation.
blood glucose in tumour-bearing mice with
increasing time after tumour transplantation, which
is significantly lower (P<0.01) than non-tumour-
bearing mice 21 days after tumour transplantation
(Figure 3).
The rates of glucose and palmitate oxidation and
CO2 and lactate production by a range of human
and murine cell lines in vitro is shown in Table I.
Of the cell lines examined only the MAC 16 is
known to produce cachexia in the host. For all cell
lines oxidation of glucose in vitro exceeds that of
palmitate by a factor of 103. Of the cell lines the
MAC 16 shows the highest conversion of both
glucose and palmitate to CO2 and the highest
conversion of glucose to lactate, even though it has
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the slowest doubling time of any of the cell lines.
These results are similar when expressed either in
terms of substrate utilization/production per cell or
per milligram of total cellular protein. The ratio of
the anerobic to aerobic utilization of glucose is high
for TLX5, L1210, L132, MAC 15A and MAC 16.
Thus it appears that the substrate requirements for
energy production by the MAC 16 tumour are high
when compared with other cell lines.
The ability of the MAC 16 tumour to utilize 3-
hydroxybutyrate as an energy source depends tipon
the presence of three enzymes - 3-hydroxybutyrate
dehydrogenase, 3 oxo acid CoA transferase and
acetoacetyl CoA thiolase. The level of these
enzymes in the MAC 16 tumour and in host tissue
is shown in Table II. There is no statistical
difference in the activity of any of these enzymes
from tissues of tumour-bearing and non tumour-
bearing mice. The tissue distribution of these
enzymes is similar to that previously reported
(Tisdale & Brennan, 1983). The activity of 3-
hydroxybutyrate dehydrogenase in all tissues is high
enough to allow for the utilization of 3-
hydroxybutyrate by metabolic oxidation. When
compared with normal colon the activity is higher
in the MAC 16 tumour suggesting no limitation on
the conversion of 3-hydroxybutyrate to aceto-
acetate.
Amongst the non-involved mouse tissues the
activity of 3 oxo acid CoA transferase is highest in
the heart and lowest in the liver as previously
reported (Fenselau & Wallis, 1974; Tisdale &
Brennan, 1983). The activity of this enzyme is lower
in the MAC 16 tumour than any other tissue,
except liver, and is significantly lower than that of
normal colon (P<0.002). Similar specific activities
were obtained with the in vitro model. The lowest
enzyme levels were found in the liver, an organ not
regarded as utilizing ketone bodies as metabolic
substrates. This result suggests that the MAC 16
tumour may have a limited capacity to metabolize
acetoacetate.
High levels of acetoacetyl CoA thiolase are found
in kidney, heart and liver. The lowest level is found
in the MAC 16 tumour and this activity is
significantly (P<0.003) lower than normal colon.
The high level of this enzyme in liver probably
reflects the role of the thiolase in processes other
than ketone body utilization.
Discussion
Tumour cells exhibit considerable flexibility in their
ability to utilize energy producing substrates in
vitro. However, a number of rapidly growing
tumours exhibit high rates of aerobic glycolysis and
lactate production. The AS-30D rat hepatoma cell
line when supplied in vitro with glucose as the only
energy source derived about 60% of the total cell
ATP from glycolysis and 40% from oxidative
phosphorylation (Nakashima et al., 1984). Some
tumours are unable to utilize fat as a metabolic
substrate due to enzyme deficiency. Thus the poorly
differentiated hepatoma 7777 exhibited low levels of
fatty acyl CoA, no appreciable activity of carnitine
palmitoyl transferase and fortified homogenates of
the tumour were unable to oxidize palmitate (Fields
et al., 1981). In general those tumours which grow
slowly and which lack the capacity for glucose
phosphorylation readily oxidize fatty acids, while
the high glycolysing tumours fail to oxidize fatty
acids (Bloch-Frankenthal et al., 1965). Zielke et al.
(1984) have also shown that oxidation of fatty acids
or ketone bodies does not contribute significantly
to the energy needs of cultured mammalian cells,
and that the apparent requirement for glucose is
related to its role in anabolic reactions. In the
Table II Activities of enzymes of ketone body metabolism in tissues ofNMR 1
mice and in the MAC 16 tumour.
Enzyme activity (iumolmin 1 mg- 1 protein) (Mean+s.e.)
3-Hydroxybutyrate 3 oxo acid CoA Acetoacetyl CoA
Tissue dehydrogenase transferase thiolase
Heart 1.1+0.5 14.2+2.21 45.7+1.3
Liver 2.9+0.6 0.3+0.17 60.0+ 13.5
Kidney 2.1+0.6 8.5+2.6 61.5+6.1
Brain 6.6+2.3 3.1+0.5 15.2+4.6
Colon 2.8+0.2 4.4+0.7 42.2+4.5
MAC 16 5.1 + 1.2a 1.7+0.5a 16.4+2.2a
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present study the rate of palmitate oxidation to
CO2 was only about one tenth the rate of CO2
production from glucose even in the MAC 16. This
low utilization of fatty acids may explain the
reduction in tumour size when the host is fed a
high fat diet. Isocaloric consumption of a diet high
in fat and protein and low in carbohydrate has
been shown to significantly prolong the survival of
MCA-sarcoma bearing rats (Demetrakopoulos &
Rosenthal, 1982) and a diet high in long chain
triglycerides reduced the number of B16 melanoma
deposits in the lungs of C57BL/6 mice by two
thirds (Magee et al., 1979). Also starvation-induced
hypoglycaemia and streptozotocin-induced diabetes
has been shown to suppress the growth of Ehrlich
ascites tumour in mice (Fung et al., 1985). In the
cell lines under study the ratio of lactate to CO2
production from glucose ranged from over 200 to
26. Thus, although the cultures were well aerated
production of lactate from glucose appears to be
the preferred metabolic reaction.
In vivo tumour architecture may play a role in
the choice of metabolic substrates. Large solid
tumours tend to be poorly vascularized on the
inside and a large fraction is consequently hypoxic.
Under conditions of low oxygen tension the
mitochondiral oxidation pathway may be non-
functional and glucose may be the only utilizable
metabolic substrate, since the Embden Meyerhoff
pathway is the only means of ATP production that
does not require oxygen. Indeed, increased Cori
cycle activity has been observed in cancer patients
with progressive weight loss, showing that lactate
production rates are higher in these patients
(Holroyde et al., 1975). If the glucose formed from
lactate in the liver is utilized by the tumour to
produce more lactate, then this represents an energy
burden on the host, which has been considered
responsible for the tumour-induced weight loss
(Gold, 1976).
The high glucose consumption by the MAC 16
tumour in vitro may be responsible for the
hypoglycaemia in the host if the same situation
occurs in vivo, although substrate utilization in vitro
may have no bearing whatsoever to the situation in
vivo. A tumour mass of 1 g of viable cells would
consume about 11 g of glucose per day, which
represents a considerable burden on the host. If the
glucose was not derived from external sources and
was obtained by gluconeogenesis from lactate the
host would need to consume an extra 3.4g of fat,
or derive it from its adipose supply, in order to
supply sufficient ATP to drive the Cori cycle. Even
a small tumour burden would impose a consider-
able strain on the host, which may account for the
rapid depletion of fat deposits in mice bearing the
MAC 16 tumour.
We and others (Tisdale & Brennan, 1983; Magee
et al., 1979; Williams & Matthaei, 1981) have
considered the possibility of reversing the cachectic
effect of certain tumours by the induction of
systemic ketosis. Metabolism of ketone bodies to
produce ATP requires oxygen and thus might be
expected to be low in the anoxic tumour fraction.
In addition the extent to which 3-hydroxybutyrate
serves as a respiratory fuel is thought to be
governed by the level of 3 oxo acid CoA transferase
(Williamson et al., 1971), although some tumours
have acquired the enzyme acetoacetyl CoA
synthetase, which enables the direct utilization of
acetoacetate (Tisdale, 1984). Levels of 3 oxo acid
CoA transferase have been reported to be decreased
or absent in a range of murine (Fields et al., 1981;
Tisdale & Brennan, 1983) and human tumours
(Fredericks & Ramsey, 1978) suggesting an
impaired ability to metabolize ketone bodies. The
MAC 16 is a well differentiated adenocarcinoma
and enzyme activity has been compared with
normal colon. On this basis MAC 16 also displays
a low activity of 3 oxo acid CoA transferase and
might be expected to metabolize 3-hydroxybutyrate
at a reduced rate. Indeed under a dietary regime in
which a high proportion of the energy is supplied
as medium chain triglycerides tumour growth is
inhibited in vivo without any alteration in the levels
of ketone body metabolizing enzymes (Tisdale et
al., 1986). These results suggest that it may be
possible to differentially feed the host at the
expense of the tumour.
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